Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse
Despite the significant cost of prescription (Rx) drug abuse and calls from policy makers for effective interventions, there is limited research on the effects of policies intended to limit such abuse. This study estimates the effects of prescription drug monitoring (PDMP) programs which is a key policy targeting the non-medical use of Rx drugs. Based on objective indicators of abuse as measured by substance abuse treatment admissions related to Rx drugs, estimates do not suggest any substantial effects of instituting an operational PDMP. We find, however, that mandatory-access provisions, which raised PDMP utilization rates by actually requiring providers to query the PDMP prior to prescribing a controlled drug, are significantly associated with a reduction in Rx drug abuse. The effects are driven primarily by a reduction in opioid abuse, generally strongest among young adults (ages 18-24), and underscore important dynamics in the policy response. Robustness checks are consistent with a causal interpretation of these effects. We also assess potential spillovers of mandatory PDMPs on the use of other illicit drugs, and find a complementary reduction in admissions related to cocaine and marijuana abuse.
We are grateful to the Agency for Healthcare Research and Quality (AHRQ) for funding support (1 R03 HS025014-01). Anca M. Grecu is grateful for the support of the Seton Hall University Research Council. Paloma Lopez de Mesa Moyano, Isaac Swensen, and Sabrina Terrizzi provided valuable comments on earlier versions of this study. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.
Anca M. Grecu & Dhaval M. Dave & Henry Saffer, 2019. "Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 38(1), pages 181-209, January. citation courtesy of